Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease

Coronary Artery Disease Clinical Trial

Official title:

A Multi-center, Prospective, Registry Study to Estimate the Current Status of Care for Patients With Coronary Artery Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05337319
• Other study ID #: NCCMRC202201_001
• Status: Recruiting
• Start date: January 17, 2022
• Est. completion date: December 30, 2028

Study information

• Verified date: May 2022
• Source: Beijing Anzhen Hospital
• Contact: Shaoping Nie, MD, PhD
• Phone: +86-10-84005255
• Email: spnie[@]ccmu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study will estimate the current status of care for participants with coronary artery disease

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100000
• Est. completion date: December 30, 2028
• Est. primary completion date: December 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized patients with discharge diagnosis as coronary artery disease (including atherosclerosis or non-athrosclerosis)

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Anzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The overall composite of 10 performance measures for CAD care	Performance measures for CAD care including: Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) Proportion of patients received reperfusion therapy (STEMI, high or moderate risk NSTE-ACS) Proportion of patients with aspirin prescribed at discharge Proportion of patients with P2Y12 inhibitors prescribed at discharge Proportion of patients with beta-blocker prescribed at discharge Proportion of patients with statin prescribed at discharge Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge Proportion of patients received evaluation of left ventricular systolic function Proportion of patients with a diagnosed non-obstructive coronary artery disease at discharge	Duration of hospital stay, an expected average of 1 week